scholarly article | Q13442814 |
P2093 | author name string | Christopher R Lines | |
Barry J Gertz | |||
David R Mandel | |||
David Borenstein | |||
Sean Curtis | |||
Agustin Melian | |||
Harris H McIlwain | |||
Alan K Matsumoto | |||
Etoricoxib Rheumatoid Arthritis Study Group | |||
Peng Liang Zhao | |||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | rheumatoid arthritis | Q187255 |
P304 | page(s) | 1623-1630 | |
P577 | publication date | 2002-08-01 | |
P1433 | published in | The Journal of Rheumatology | Q7743623 |
P1476 | title | A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis | |
P478 | volume | 29 |
Q24794291 | A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]. |
Q24615651 | A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity |
Q24796193 | COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients |
Q34847583 | Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib |
Q34713083 | Clinical use and pharmacological properties of selective COX-2 inhibitors |
Q38262502 | Comparative evaluation of cardiovascular outcomes in patients with osteoarthritis and rheumatoid arthritis on recommended doses of nonsteroidal anti-inflammatory drugs |
Q36861909 | Comparison of benefit-risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments |
Q24796005 | Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors |
Q44971339 | Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. |
Q38993297 | Efficacy and tolerability of naproxen/esomeprazole magnesium tablets compared with non-specific NSAIDs and COX-2 inhibitors: a systematic review and network analyses |
Q91639695 | Erratum to "Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac" |
Q35016968 | Etoricoxib |
Q35166773 | Etoricoxib for arthritis and pain management |
Q34610283 | Etoricoxib: a review of its use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and acute gouty arthritis |
Q36098013 | Evaluation of two doses of etoricoxib, a COX-2 selective non-steroidal anti-inflammatory drug (NSAID), in the treatment of Rheumatoid Arthritis in a double-blind, randomized controlled trial |
Q48269682 | Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis |
Q36013803 | Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials |
Q42695576 | Pivotal factors for successful withdrawal of nonsteroidal anti-inflammatory drugs in rheumatoid arthritis patients in remission or with low-disease activity |
Q37893966 | Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors |
Q35028375 | The second generation of COX-2 inhibitors: what advantages do the newest offer? |
Search more.